Marcel Kordt

Dr. Marcel Kordt


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 June 2023 in Journal of Advanced Research
Verified
Journal Article
Open access
LBLars Boeckmann
Lars Boeckmann
JBJulia Berner
Julia Berner
MKMarcel Kordt
Marcel Kordt
ELElea Lenz
Elea Lenz
MSMirijam Schäfer
Mirijam Schäfer
Sander BekeschusSander Bekeschus
Sander Bekeschus
Skin cancer is often fatal, which motivates new therapy avenues. Recent advances in cancer treatment are indicative of the importance of combination treatments in oncology. Previous studies have identified small molecule-based therapies and redox-based technologies, including photodynamic therapy or medical gas plasma, as promising candidates to target skin cancer. We aimed to identify effective combinations of experimental small molecules with cold gas plasma for therapy in dermato-oncology. Promising drug candidates were identified after screening an in-house 155-compound library using 3D skin cancer spheroids and high content imaging. Combination effects of selected drugs and cold gas plasma were investigated with respect to oxidative stress, invasion, and viability. Drugs that had combined well with cold gas plasma were further investigated in vascularized tumor organoids in ovo and a xenograft mouse melanoma model in vivo. The two chromone derivatives Sm837 and IS112 enhanced cold gas plasma-induced oxidative stress, including histone 2A.X phosphorylation, and further reduced proliferation and skin cancer cell viability. Combination treatments of tumor organoids grown in ovo confirmed the principal anti-cancer effect of the selected drugs. While one of the two compounds exerted severe toxicity in vivo, the other (Sm837) resulted in a significant synergistic anti-tumor toxicity at good tolerability. Principal component analysis of protein phosphorylation profiles confirmed profound combination treatment effects in contrast to the monotherapies. We identified a novel compound that, combined with topical cold gas plasma-induced oxidative stress, represents a novel and promising treatment approach to target skin cancer.

19 May 2021 in Cancers
Verified
Journal Article
Open access
PDF file
MKMarcel Kordt
Marcel Kordt
ITIsabell Trautmann
Isabell Trautmann
CSChristin Schlie
Christin Schlie
TLTobias Lindner
Tobias Lindner
JSJan Stenzel
Jan Stenzel
EGEberhard Grambow
Eberhard Grambow
Background: Skin cancer is the most frequent cancer worldwide and is divided into non-melanoma skin cancer, including basal cell carcinoma, as well as squamous cell carcinoma (SCC) and malignant melanoma (MM). Methods: This study evaluates the effects of cold atmospheric pressure plasma (CAP) on SCC and MM in vivo, employing a comprehensive approach using multimodal imaging techniques. Longitudinal MR and PET/CT imaging were performed to determine the anatomic and metabolic tumour volume over three-weeks in vivo. Additionally, the formation of reactive species after CAP treatment was assessed by non-invasive chemiluminescence imaging of L-012. Histological analysis and immunohistochemical staining for Ki-67, ApopTag®, F4/80, CAE, and CD31, as well as protein expression of PCNA, caspase-3 and cleaved-caspase-3, were performed to study proliferation, apoptosis, inflammation, and angiogenesis in CAP-treated tumours. Results: As the main result, multimodal in vivo imaging revealed a substantial reduction in tumour growth and an increase in reactive species after CAP treatment, in comparison to untreated tumours. In contrast, neither the markers for apoptosis, nor the metabolic activity of both tumour entities was affected by CAP. Conclusions: These findings propose CAP as a potential adjuvant therapy option to established standard therapies of skin cancer.

9 May 2022 in Molecules
Verified
Journal Article
Open access
PDF file
AFAlica Fischle
Alica Fischle
RSRico Schwarz
Rico Schwarz
FWFranziska Wendt
Franziska Wendt
MKMarcel Kordt
Marcel Kordt
RRRobert Ramer
Robert Ramer
BHBurkhard Hinz
Burkhard Hinz
Indirubin was identified as an active component of Danggui Longhui Wan, an herbal mixture used in traditional Chinese medicine, and showed anticancer activity in clinical trials in patients with chronic leukemia. Investigations on the mechanisms of antitumor action of indirubins have mainly focused on the indirubin derivative indirubin-3′-monoxime (I3M). Meanwhile, antiproliferative and cytotoxic properties on cancer cells have also been demonstrated for several synthetic indirubin N-glycosides. In the present study, we demonstrate cytotoxic activity of the thia-analogous indirubin N-glycosides KD87 (3-[3′-oxo-benzo[b]thiophen-2′-(Z)-ylidene]-1-(β-d-glucopyranosyl)-oxindole) and KD85 (3-[3′-oxo-benzo[b]thiophen-2′-(Z)-ylidene]-1-(β-d-mannopyranosyl)-oxindole) against melanoma and squamous cell carcinoma cells as well as lung cancer and glioblastoma cells. The advanced state of preclinical studies on the effects of indirubins conducted to date underscores the need for pharmacokinetic data from cellular, animal, and human studies for which reliable quantification is required. Therefore, a sensitive liquid chromatography-tandem mass spectrometric (LC-MS/MS) method was developed and validated for the simultaneous measurement of KD87, KD85, and I3M in plasma and cell culture medium. Experimental conditions for sample preparation were optimized for human plasma protein precipitation and liquid-liquid extraction from plasma and cell culture medium. The methods were successfully validated in accordance with the U.S. Food and Drug Administration Bioanalytical Method Validation and evaluated for selectivity, sensitivity, matrix effect, recovery, carryover, calibration curve linearity, accuracy, precision, and stability. The applicability of the methods was demonstrated by the determination of KD87 in mouse plasma after prior intraperitoneal administration to mice.

21 July 2021 in Animals
Verified
Journal Article
Open access
PDF file
WXWentao Xie
Wentao Xie
MKMarcel Kordt
Marcel Kordt
RPRupert Palme
Rupert Palme
EGEberhard Grambow
Eberhard Grambow
BVBirgitte Vollmar
Birgitte Vollmar
DZDietmar Zechner
Dietmar Zechner
Subcutaneous tumor models in mice are the most commonly used experimental animal models in cancer research. To improve animal welfare and the quality of scientific studies, the distress of experimental animals needs to be minimized. For this purpose, one must assess the diagnostic ability of readout parameters to evaluate distress. In this study, we evaluated different noninvasive readout parameters such as body weight change, adjusted body weight change, faecal corticosterone metabolites concentration, burrowing activity and a distress score by utilising receiver operating characteristic curves. Eighteen immunocompromised NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ mice were used for this study; half were subcutaneously injected with A-375 cells (human malignant melanoma cells) that resulted in large tumors. The remaining mice were inoculated with SCL-2 cells (cutaneous squamous cell carcinoma cells), which resulted in small tumors. The adjusted body weight and faecal corticosterone metabolites concentration had a high diagnostic ability in distinguishing between mice before cancer cell injection and mice bearing large tumors. All other readout parameters had a low diagnostic ability. These results suggest that adjusted body weight and faecal corticosterone metabolites are useful to depict the distress of mice bearing large subcutaneous tumors.

26 March 2026 in Journal of Cellular and Molecular Medicine
Verified
Journal Article
Open access
MKMarcel Kordt
Marcel Kordt
WBWendy Bergmann‐Ewert
Wendy Bergmann‐Ewert
JAJohann Aleith
Johann Aleith
Sander BekeschusSander Bekeschus
Sander Bekeschus
BMBrigitte Müller‐Hilke
Brigitte Müller‐Hilke
Rheumatoid arthritis (RA) is driven by hyperplastic fibroblast‐like synoviocytes (FLS) that adopt a persistent inflammatory and invasive phenotype, often resistant to conventional therapies. Here, we investigated whether cold gas plasma exposure modulates inflammatory FLS (iFLS) in vitro. Primary murine FLS were primed with TNF‐α to induce an inflammatory phenotype and exposed to an argon plasma jet for 30–150 s; argon gas alone served as a control. Gas plasma treatment caused a rapid, dose‐dependent rise in intracellular reactive oxygen species and free thiols, followed by partial resolution by 24 h. This oxidative burst coincided with mitochondrial dysfunction and progressive loss of cell viability. Surviving iFLS exhibited markedly reduced inflammatory features, such as surface levels of ICAM‐1 (CD54), VCAM‐1 (CD106), and Thy‐1 (CD90.2), along with diminished production of IL‐6 and CCL2 at higher doses. Reflecting the impaired expression of inflammation‐associated adhesion molecules. Furthermore, plasma treatment significantly delayed iFLS migration. Together, these findings suggest that cold gas plasma has cytotoxic effects on a subset of iFLS induced by acute oxidative stress, as well as reprogramming surviving iFLS towards a less aggressive phenotype. These in vitro data establish a foundation for further research in synovial explants and arthritis models, as well as for systematic safety testing in non‐inflammatory joint‐resident cells.